NSYSHIGH SIGNALFINANCIAL10-K

NSYS achieved a dramatic operational turnaround with operating income swinging from -$195K to +$975K and operating cash flow improving from -$2.3M to +$2.7M, though this was accompanied by a near-doubling of total debt to $7.1M.

The company has successfully executed a significant operational recovery, moving from operating losses to profitability while generating strong positive cash flow. However, the 95% increase in debt raises questions about the sustainability of this turnaround and whether it was achieved through increased leverage rather than purely operational improvements.

Comparing 2026-03-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

NSYS demonstrated a remarkable financial turnaround with operating income improving by 600% to positive territory and operating cash flow swinging dramatically from negative $2.3M to positive $2.7M. The company strengthened its liquidity position with cash increasing 81% to $1.7M while reducing capital expenditures by 48%, though current liabilities increased 39% and total debt nearly doubled to $7.1M. Overall, the results suggest successful operational improvements and cash generation, but the significant debt increase indicates the recovery may have been partially financed through increased borrowing, warranting close monitoring of debt service capabilities.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+600%
-$195K$975K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+221.9%
-$2.3M$2.7M

Operating cash flow surged 221.9% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
+95.1%
$3.6M$7.1M

Debt increased 95.1% — substantial leverage increase; assess whether deployed for growth or covering losses.

Cash & Equivalents
Balance Sheet
+80.7%
$916K$1.7M

Cash position surged 80.7% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+80.5%
-$1.3M-$252K

Net income grew 80.5% — bottom-line growth signals improving overall business health.

Share Buybacks
Cash Flow
-52.9%
$276K$130K

Buyback activity reduced 52.9% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-48%
$1.3M$661K

Capex reduced 48% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+39.3%
$21.4M$29.8M

Current liabilities surged 39.3% — significant near-term obligations; verify ability to meet short-term debt.

Accounts Receivable
Balance Sheet
+14.3%
$14.9M$17.0M

Receivables grew 14.3% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-31
ADDED
Exhibits and Financial Statement Schedules 55 Signatures 56 Index to Exhibits 57 2 NORTECH SYSTEMS INCORPORATED FORM 10-K For the Year Ended December 31, 2025 PART I Item 1.
Additionally, our facility in Monterrey, Mexico is now certified in AS9100:D.
Food and Drug Administration ( FDA ) registered facility, and our Suzhou operation is National Medical Products Administration certified for class II medical devices.
We seek to develop, in partnership with our customers, a commitment to strong supplier partnerships and risk management tools through advanced supply chain solutions.
4 Major Customers One customer individually accounted for 32.2% of net sales for the year ended December 31, 2025 and 27.7% of net sales for the year ended December 31, 2024.
+7 more — sign up free →
REMOVED
Exhibits and Financial Statement Schedules 53 Signatures 54 Index to Exhibits 55 2 NORTECH SYSTEMS INCORPORATED FORM 10-K For the Year Ended December 31, 2024 PART I Item 1.
Food and Drug Administration ( FDA ) registered facility, and our Suzhou operation is a China National Medical Imaging Administration certified facility.
We attempt to overcome these changes through advanced supply chain solutions we develop in partnership with our customers, a commitment to strong supplier partnerships and risk management tools.
4 Major Customers One customer individually, accounted for at 27.7% of net sales for the year ended December 31, 2024, and two customers, individually, accounted for 25.7% and 10.3%, respectively, of net sales for the year ended December 31, 2023.
We spent approximately $1.2 million on product research and development in each of the years ended December 31, 2024 and 2023.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →